Quantifying the Impact of Switching From Rotarix to Rotavac Rotavirus Vaccine in Ghana
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiag003 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Ernest O Asare und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, Connecticut USA. Hauptthemen laut MEDLINE: Rotavirus Vaccines, Rotavirus Infections. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health/National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Abstract (Originalsprache)
Background
Ghana introduced the Rotarix vaccine in April 2012 and switched to the Rotavac vaccine in January 2020. Evaluating the health impact of this change is essential for national policy and can inform decisions in other countries.
Methods
We applied a previously validated mathematical model of rotavirus transmission in Navrongo, Ghana, to quantify the health impact of switching from Rotarix to Rotavac among children under 2. We first simulated the model from January 2007 to December 2019 using previously estimated model parameters from pre- and post-Rotarix surveillance data. We then refitted the model to data from January 2020 to March 2023 to estimate Rotavac vaccine effectiveness parameters. To assess overall vaccine effectiveness (OVE), we compared model simulations under the 2 vaccination scenarios (Rotarix and Rotavac) with a counterfactual scenario assuming no vaccination.
Results
The model accurately captured both the trend and seasonality of postvaccination rotavirus cases, with a Spearman correlation of 0.70. Compared to the no-vaccination scenario, the estimated OVE against moderate-to-severe rotavirus cases was 21.7% (95% prediction interval [PI]: 17.4%–26.1%) in children under 2 years in Navrongo. Annual OVE ranged from 8.4% (PI: 1.0%–21.0%) to 63.5% (PI: 39.0%–87.0%). Following the switch from Rotarix to Rotavac (2020–2023), we estimated a mean relative OVE of 37.1% (PI: 27.5%–46.5%).
Conclusions
Our model offers a robust tool to support policymakers in Ghana and similar settings by evaluating current rotavirus vaccine effectiveness, guiding vaccine switching decisions and informing introduction strategies in countries yet to adopt immunization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, Connecticut USA.
- Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, Connecticut USA.
- Department of Electron Microscopy and Histopathology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
ORCID-Profile: Ernest O Asare
Förderung
- NIAID NIH HHS
- National Institutes of Health/National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Asare, E. O., Lartey, B. L., Armah, G. E., & Pitzer, V. E. (2026). Quantifying the Impact of Switching From Rotarix to Rotavac Rotavirus Vaccine in Ghana. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag003
Vancouver
Asare EO, Lartey BL, Armah GE, Pitzer VE. Quantifying the Impact of Switching From Rotarix to Rotavac Rotavirus Vaccine in Ghana. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag003
BibTeX
@article{Asare2026,
author = {Asare, Ernest O and Lartey, Belinda L and Armah, George E and Pitzer, Virginia E},
title = {Quantifying the Impact of Switching From Rotarix to Rotavac Rotavirus Vaccine in Ghana},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag003}
}
EUVIMED